Learning Objectives
After reading this article, the
reader should be able to: (1) Discuss the
worldwide prevalence of erectile dysfunction and
the risk factors that cause it. (2) Describe the
physiology of an erection and the role
phosphodiesterase enzyme 5 (PDE5) and PDE5
inhibitors play in it. (3) Understand the
effectiveness (including efficacy in multiple
patient populations, onset of action, duration
of effect, and drug–drug/drug–food interactions)
and safety of each of the PDE5 inhibitors.
In the past, erectile
dysfunction (ED) was taboo for public
discussion, but it has now gained social and
medical recognition as a condition affecting
millions of men. More than a decade ago, a
National Institutes of Health Consensus
Conference defined ED as "the consistent
inability to achieve and maintain a penile
erection adequate for satisfactory sexual
intercourse."1 The word consistent is
used because an occasional episode of ED
occurring in men is normal.
An estimated 150 million men
worldwide have some degree of ED, and more than
twice that many are expected to be affected by
2025.2 Given that age-related
hormonal changes contribute to the overall
prevalence, the impact of ED has particular
implications for the United States, where the
population is expected to grow increasingly
older in the coming years.
Scope of the Problem
The historical view of ED as a
private matter has complicated efforts to
determine the prevalence of the condition. Some
of the first systematically collected data came
from the Massachusetts Male Aging Study (MMAS),
a survey of 1700 men aged 40 to 70 years.3
Responses to the survey showed that 52% of
the men reported some degree of ED. The MMAS
data also documented an age-related increase in
prevalence, as 40% of men aged 40 to 49
complained of mild, moderate, or severe ED,
increasing to almost 70% of men aged 70 to 79. A
majority of men 60 years or older reported
moderate or severe ED.
An update of MMAS showed that
the incidence of ED increased about 2-fold with
each decade of life.4 Extrapolation
of that data to the US population would result
in an estimated 617 715 new cases of ED each
year among white men 40 to 70 years old.5
Another US study of 2115 men,
aged 40 to 79 years, revealed an overall
prevalence of severe ED (defined as having
erections infrequently or not at all in response
to stimulation) of 11.6%. Prevalence increased
from 1% among the youngest men to 25% in the
oldest age group.6
Studies involving men from
other countries have demonstrated that high
rates of reported ED are not limited to the
United States. The Cologne Male Survey showed a
19.2% prevalence of ED among 4489 German men
aged 30 to 80 years. The study also documented a
sharp age-related increase in prevalence.7
An Australian study involving general
medical practitioners showed a 34% prevalence of
ED among male patients, including complete
inability to achieve an erection in 12% of the
men.8 Other studies have demonstrated
rates of ED ranging between 5% and 55%.9
Risk Factors for ED
ED was once considered
primarily a psychogenic disorder, but that view
has given way to evidence showing that a variety
of factors can adversely affect the ability to
achieve an erection, including numerous medical
conditions.5,9 Some studies have
indicated that the vast majority of cases have
an organic etiology (Table).10-12
Vascular disorders,
particularly atherosclerosis, are thought to be
the most common organic causes of ED.12
Some evidence suggests ED is a marker for
underlying cardiovascular disease. For example,
a study of almost 1000 men seeking consultation
for ED showed that 18% had undiagnosed
hypertension, 16% had diabetes, and 5% had
ischemic heart disease.13
In general, conditions that
cause peripheral vascular disease adversely
affect penile arteries and can lead to ED.
Examples include hypertension, diabetes,
dyslipidemia, and smoking.5 The
association has led some authorities to conclude
that treatment of risk factors for vascular
disease offers a promising but never proven
approach to prevention of ED.14
Diabetes has a particularly strong
association with ED. In MMAS, 28% of men with
diabetes reported complete impotence, compared
with 10% of the population without
diabetes.3 Studies in other countries
have found that as many as 60% of men with
diabetes report varying degrees of ED.9
Other potential causes of ED
include neurologic disorders and injuries,
hormonal abnormalities, alcohol abuse, obesity,
and certain prescription medications.
Psychogenic factors still
contribute to some cases of ED and should not be
discounted in the evaluation of a patient. These
factors often manifest as circumstantial or
situational dysfunction or performance
anxiety.5
Summary
ED affects millions of men
worldwide and increases in prevalence with age.
Men report varying degrees of difficulty in
achieving and maintaining erections throughout
the world. Once considered primarily a
psychogenic disorder, ED now has a
well-established association with a variety of
organic causes, vascular disease being among the
most prominent. By recognizing the prevalent
nature of ED and it association with organic
causes, clinicians will be better prepared to
diagnose and treat the condition.
References
1. National Institutes of
Health. Impotence. NIH Consensus Statement.
1992;10:1-33.
2. Ayta IA, McKinlay JB, Krane
RJ. The likely worldwide increase in erectile
dysfunction between 1995 and 2025 and some
possible policy consequences. BJU Int.
1999;84:50-56.
3. Feldman HA, Goldstein I,
Hatzichristou DG, et al. Impotence and its
medical and psychosocial correlates. Results of
the Massachusetts Male Aging Study. J
Urol. 1994;151:54-61.
4. Johannes CB, Araujo AB,
Feldman HA, et al. Incidence of erectile
dysfunction in men ages 40-69. Longitudinal
results from the Massachusetts Male Aging Study.
J Urol. 2000;163:460-463.
5. Carbone DJ Jr, Seftel AD.
Erectile dysfunction. Diagnosis and treatment in
older men. Geriatrics. 2002;57:18-24.
6. Panser LA, Rhodes T, Girman
CJ, et al. Sexual function of men aged 40 to 79
years: the Olmsted County Study of urinary
symptoms and health status among men. J Am
Geriatr Soc. 1995;43:1107-1111.
7. Braun M, Wassmer G, Klotz T,
et al. Epidemiology of erectile dysfunction:
results of the Cologne Male Survey. Int J
Impot Res. 2000;12:305-311.
8. Chew KK, Earle CM, Stuckey
BG, et al. Erectile dysfunction in general
medicine practice: prevalence and clinical
correlates. Int J Impot Res.
2000;12:41-45.
9. Kubin M, Wagner G,
Fugl-Meyer AR. Epidemiology of erectile
dysfunction. Int J Impot Res.
2003;15:63-71.
10. Lee IC, Surridge D, Morales
A, et al. The prevalence and influence of
significant psychiatric abnormalities in men
undergoing comprehensive management of organic
erectile dysfunction. Int J Impot Res.
2000; 12:47-51.
11. Araujo AB, Johannes CB,
Feldman HA, et al. Relation between psychosocial
risk factors and incidence of erectile
dysfunction: prospective results from the
Massachusetts Male Aging Study. Am J
Epidemiol. 2000;152:533-541.
12. Sullivan ME, Keoghane SR,
Miller MA. Vascular risk factors and erectile
dysfunction. BJU Int.
2002;87:838-845.
13. Kirby M, Jackson G,
Betteridge J, et al. Is erectile dysfunction a
marker for cardiovascular disease? Int J Clin
Pract. 2001;55:614-618.
14. Andersson KE, Hedlund P.
New directions for erectile dysfunction
therapies. Int J Impot Res. 2002;14(suppl
1):S82-S92.